#Canada #Montreal #Find Therapeutics #Dr. Nancy Messier #Dr. Thierry Abribat

Find Therapeutics Welcomes New Expertise to its Board

Find Therapeutics Inc., a biopharmaceutical company committed to creating cutting-edge therapies for autoimmune diseases, has recently appointed Dr. Nancy Messier and Dr. Thierry Abribat to its Board of Directors. This strategic move aims to enhance the company's mission and support its ongoing research and development initiatives.

As the biopharmaceutical landscape evolves, having experts with a wealth of experience in drug discovery, clinical development, and business strategy is vital. With Dr. Messier and Dr. Abribat joining the team, Find Therapeutics is well-positioned to capitalize on their complementary skills to drive innovation and progress.

Meet Dr. Nancy Messier

Dr. Nancy Messier serves as the Vice President of Drug Discovery at Feldan Therapeutics. Her role involves steering drug discovery and preclinical development, particularly focusing on the Shuttle, a pioneering peptide-based intracellular delivery system. Notably, Dr. Messier's work on the intralesional treatment of basal cell carcinoma is set to enter clinical trials, marking a significant step in her research endeavors.

Dr. Messier earned her PhD in microbiology from Laval University, where she specialized in antibiotic resistance at the Infectious Disease Research Center in Quebec City. Her extensive knowledge in microbiology and drug discovery ensures that she brings valuable insights to Find Therapeutics as the company progresses with its innovative therapies.

Introducing Dr. Thierry Abribat

Dr. Thierry Abribat is not just an executive; he is a serial entrepreneur with a notable track record in the biotech realm. Having founded and successfully managed three biotech firms, he has been directly involved in developing impactful drugs and generating returns for investors. His companies include Alizé Pharma and Amolyt Pharma, both of which have seen successful acquisitions, demonstrating his aptitude for steering startups toward success.

With an academic background in veterinary medicine and a PhD in neuroendocrinology from the National Polytechnic Institute of Toulouse, Dr. Abribat provides a wealth of knowledge from his extensive experience in drug development and business management. His previous roles include Chief Scientific Officer at Theratechnologies and Chief Operating Officer at OPi SA, roles which have further cemented his expertise in both scientific and operational aspects of the biotech industry.

The FTX-101 Initiative

Find Therapeutics is renowned for its lead compound, FTX-101, which is designed to be a first-in-class remyelinating agent. This innovative treatment aims to restore vision for individuals suffering from Chronic Optic Neuropathy, a condition that significantly impacts quality of life. The compound has shown promising results in preclinical studies, showcasing its potential to repair the myelin sheath, which is crucial for the health of optic nerves.

The mechanism of action of FTX-101 involves targeting Plexin A1 and Neuropilin 1, receptors known to play a pivotal role in the development of oligodendrocytes, which are responsible for myelin production. Given the strong myelin repair activity observed in preclinical models, there is high optimism surrounding the potential of this novel therapy.

Closing Thoughts

As Find Therapeutics prepares to navigate the next phases of its clinical studies, the addition of Dr. Messier and Dr. Abribat to the Board is expected to provide essential guidance and expertise. With their insights, Find Therapeutics will continue to be at the forefront of developing groundbreaking therapies for autoimmune disorders, ultimately striving to improve patients' lives.

Stay tuned as the journey of Find Therapeutics unfolds with its exciting advancements in the field of autoimmune disease therapies.